Founded in Boston, Massachusetts, Vertex Pharmaceuticals is a biotechnology company dedicated to discovering and commercializing therapies for serious diseases, with a primary focus on cystic fibrosis (CF). The company's core mission is to transform the lives of people with serious diseases through scientific innovation. Vertex markets several CF treatments, including TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting various CF mutations and age groups.
Vertex has garnered significant attention and investment from notable figures in the biotechnology and pharmaceutical industries. The company's groundbreaking work in CF treatment has led to substantial improvements in patient outcomes, earning it a reputation as a leader in the field. Vertex's achievements include the successful commercialization of multiple CF therapies and ongoing research into other serious diseases, underscoring its impact on healthcare and patient lives globally.

PTC Therapeutics
ptcbio.com

Synspira

Gilead Sciences
gilead.com

Vertice Pharma

cystetic Medicines

Sionna Therapeutics
sionnatx.com

Astria Therapeutics
astriatx.com

Amylyx Pharmaceuticals
amylyx.com

Pulmatrix
pulmatrix.com

BioCryst Pharmaceuticals
biocryst.com

Insmed
insmed.com

Theravance Biopharma
theravance.com

Boston Biopharma

Variant Pharmaceuticals
variantpharma.com

Blueprint Medicines
Companies similar to Vertex Pharmaceuticals include PTC Therapeutics, Synspira, Gilead Sciences and Vertice Pharma.
Vertex Pharmaceuticals was founded in 1989.
Vertex Pharmaceuticals' headquarters is located in Boston, MA, US.
Vertex Pharmaceuticals' most recent funding round was for $50M (USD) in May 2022.
As of May 17, 2022, Vertex Pharmaceuticals has raised a total of $656.2M (USD).
Vertex Pharmaceuticals has 4,800 employees as of Feb 6, 2024.